Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial

Bibliografske podrobnosti
Main Authors:	Rocca, B, Buck, G, Petrucci, G, Parish, S, Pagliaccia, F, Baigent, C, Mafham, M, Bowman, L, Armitage, J, Patrono, C
Drugi avtorji:	The ASCEND Study Collaborative Group
Format:	Conference item
Jezik:	English
Izdano:	Oxford University Press 2020

Podobne knjige/članki

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
od: Petrucci, G, et al.
Izdano: (2024)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
od: Parish, S, et al.
Izdano: (2023)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
od: Aung, T, et al.
Izdano: (2017)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
od: Sarah Parish, et al.
Izdano: (2023-03-01)

Measurement of Thromboxane Biosynthesis in Health and Disease
od: Carlo Patrono, et al.
Izdano: (2019-10-01)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
od: Harper, C, et al.
Izdano: (2021)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
od: Parish, S, et al.
Izdano: (2022)

ASCEND-Eye: effects of aspirin on diabetic retinopathy
od: Sammons, E, et al.
Izdano: (2024)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
od: Harper, C, et al.
Izdano: (2021)

ASCEND-Eye: effects of omega-3 fatty acids on diabetic retinopathy
od: Sammons, E, et al.
Izdano: (2023)

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
od: Mafham, MM, et al.
Izdano: (2019)

ASCEND-eye: rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
od: Sammons, E, et al.
Izdano: (2023)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
od: Sammons, EL, et al.
Izdano: (2024)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
od: Sammons, EL, et al.
Izdano: (2024)

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
od: Emily Sammons, et al.
Izdano: (2023-10-01)

Foetal vascular responses to thromboxane receptor blockade
od: B. A. Meyer, et al.
Izdano: (1992-01-01)

Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation
od: Giovanna Petrucci, et al.
Izdano: (2022-12-01)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
od: Bowman, L, et al.
Izdano: (2017)

Urinary leukotriene E4 and 11-dehydro-thromboxane B2 excretion in children with bronchial asthma
od: Kaori Yoshikawa, et al.
Izdano: (2004-01-01)

Thromboxane Modulates Endothelial Permeability
od: J. M. Klausner, et al.
Izdano: (1994-01-01)

Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
od: Thomas J Montine, et al.
Izdano: (2010-02-01)

Effects of Fatty Acid Metabolites on Adipocytes Britening: Role of Thromboxane A2
od: Cécilia Colson, et al.
Izdano: (2023-01-01)

Stability of thromboxane in blood samples
od: Helgadóttir H, et al.
Izdano: (2019-06-01)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
od: Emily L. Sammons, et al.
Izdano: (2024-11-01)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
od: Mafham, M, et al.
Izdano: (2011)

Peroxisomal chain-shortening of thromboxane B2: evidence for impaired degradation of thromboxane B2 in Zellweger syndrome
od: U Diczfalusy, et al.
Izdano: (1993-07-01)

What is the association of COVID-19 with heart attacks and strokes?
od: Mafham, M, et al.
Izdano: (2021)

Effects of omega−3 fatty acid supplements on arrhythmias
od: Parish, S, et al.
Izdano: (2020)

Selective COX-2 inhibitors: where do we go from here?
od: Baigent, C, et al.
Izdano: (2008)

Coxibs, traditional NSAIDs and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now
od: Patrono, C, et al.
Izdano: (2017)

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
od: Patrono, C, et al.
Izdano: (2010)

Selective COX-2 inhibitors: where do we go from here?
od: Baigent, C, et al.
Izdano: (2008)

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
od: Baigent, C, et al.
Izdano: (2003)

Nonsteroidal anti-inflammatory drugs and the heart.
od: Patrono, C, et al.
Izdano: (2014)

Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
od: Patrono, C, et al.
Izdano: (2009)

Role of aspirin in primary prevention of cardiovascular disease
od: Patrono, C, et al.
Izdano: (2019)

Investigation of the Excretion of Triamcinolone Acetonide and Its Metabolite
od: Dorota Kwiatkowska, et al.
Izdano: (2023-02-01)

ADP and Thromboxane Inhibitors Both Reduce Global Contraction of Clot Length, While Thromboxane Inhibition Attenuates Internal Aggregate Contraction
od: Kevin T. Trigani, et al.
Izdano: (2022-04-01)

Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
od: Clarke, R, et al.
Izdano: (1991)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
od: Emberson, JR, et al.
Izdano: (2010)